A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of age

A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of age

Streptococcus pneumoniae causes a considerable disease burden among children in China. Many isolates exhibit antimicrobial resistance but are often serotypes covered by the 13-valent pneumococcal conjugate vaccine (PCV13). Because the approved infant immunization schedule in China allows PCV13 vacci...

Full description

Bibliographic Details
Main Authors: Kai Chu, Yuemei Hu, Hongxing Pan, Jingliang Wu, Dandan Zhu, Mariano M. Young, Li Luo, Zhuobiao Yi, Peter C. Giardina, William C. Gruber, Daniel A. Scott, Wendy Watson
Format: Article
Language:English
Published: Taylor & Francis Group 2023-08-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
china
clinical trial
immunogenicity
pcv13
pediatric
pneumococcal conjugate vaccine
pneumococcal disease
safety
streptococcus pneumoniae
Online Access:http://dx.doi.org/10.1080/21645515.2023.2235926

Similar Items

Similar Items